Dabigatran Etexalate Mesylate

Takaitaccen Bayani:

Sunan API Nuni Ƙayyadaddun bayanai Farashin DMF EU DMF CEP
Dabigatran Etexalate Mesylate Anticoagulant Cikin Gida      


Cikakken Bayani

Tags samfurin

BAYANIN KYAUTA

Bayani

Dabigatran etexilate mesylate (BIBR 1048MS) prodrug ne mai aiki da baki na Dabigatran. Dabigatran etexilate mesylate yana da tasirin anticoagulant kuma ana amfani dashi don rigakafin venousthromboembolism da bugun jini saboda fibrillation na atrial.

Fage

Bayani: IC50 Darajar: 4.5nM (Ki); 10nM (Thrombin-induced platelet aggregation) [1] Dabigatran mai juyawa ne kuma mai zaɓi, mai hana thrombin kai tsaye (DTI) yana fuskantar ci gaba na asibiti a matsayin prodrug na baki, dabigatran etexilate. in vitro: Dabigatran selectively da reversibly hana ɗan adam thrombin (Ki: 4.5 nM) da kuma thrombin-induced platelet aggregation (IC(50): 10 nM), yayin da nuna wani inhibitory sakamako a kan sauran platelet-stimulating agents.Thrombin ƙarni a cikin platelet. Plasma mara kyau (PPP), wanda aka auna kamar yadda aka hana yiwuwar thrombin endogenous (ETP) maida hankali dogara (IC(50): 0.56 microM). Dabigatran ya nuna tasirin anticoagulant mai dogara da maida hankali a cikin nau'ikan nau'ikan in vitro, yana ninka lokacin thromboplastin da aka kunna (aPTT), lokacin prothrombin (PT) da lokacin clotting ecarin (ECT) a cikin PPP na ɗan adam a ƙimar 0.23, 0.83 da 0.18 microM, bi da bi. 1]. a cikin vivo: Dabigatran ya tsawaita adadin aPTT-dogara bayan gudanarwar jijiya a cikin berayen (0.3, 1 da 3 mg/kg) da birai rhesus (0.15, 0.3 da 0.6 mg/kg). An lura da tasirin maganin rigakafi na lokaci- da lokaci tare da dabigatran etexilate da aka gudanar da baki ga berayen masu hankali (10, 20 da 50 mg / kg) ko birai rhesus (1, 2.5 ko 5 mg / kg), tare da matsakaicin tasirin da aka lura tsakanin 30 da 120 min bayan gudanarwa, bi da bi [1]. Marasa lafiya da aka yi wa dabigatran etexilate sun sami ƙarancin bugun jini na ischemic (3.74 dabigatran etexilate vs 3.97 warfarin) da ƙarancin haɗuwa da zubar jini na ciki da bugun jini na jini (0.43 dabigatran etexilate vs 0.99 warfarin) a cikin 1020 haƙuri [shekaru]. Gwajin gwaji na asibiti: Ƙididdigar Pharmacokinetics da Pharmacodynamics na Oral Dabigatran Etexilate a cikin marasa lafiya na Hemodialysis. Mataki na 1

Adana

Foda

-20°C

shekaru 3
 

4°C

shekaru 2
A cikin ƙarfi

-80°C

Wata 6
 

-20°C

Wata 1

Gwajin asibiti

Lambar NCT Mai tallafawa Yanayi Ranar farawa

Mataki

Saukewa: NCT02170792 Boehringer Ingelheim Lafiyayyan Fabrairu 2001

Mataki na 1

Saukewa: NCT02170974 Boehringer Ingelheim Lafiyayyan Yuli 2004

Mataki na 1

Saukewa: NCT02170831 Boehringer Ingelheim Lafiyayyan Mayu 1999

Mataki na 1

Saukewa: NCT02170805 Boehringer Ingelheim Lafiyayyan Afrilu 2001

Mataki na 1

Saukewa: NCT02170610 Boehringer Ingelheim Lafiyayyan Maris 2002

Mataki na 1

Saukewa: NCT02170909 Boehringer Ingelheim Lafiyayyan Disamba 2004

Mataki na 1

Saukewa: NCT02171000 Boehringer Ingelheim Lafiyayyan Afrilu 2005

Mataki na 1

Saukewa: NCT02170844 Boehringer Ingelheim Lafiyayyan Yuni 2004

Mataki na 1

Saukewa: NCT02170584 Boehringer Ingelheim Lafiyayyan Janairu 2001

Mataki na 1

Saukewa: NCT02170935 Boehringer Ingelheim Venous Thromboembolism Afrilu 2002

Mataki na 2

Saukewa: NCT02170636 Boehringer Ingelheim Lafiyayyan Janairu 2002

Mataki na 1

Saukewa: NCT02170766 Boehringer Ingelheim Lafiyayyan Oktoba 2000

Mataki na 1

Saukewa: NCT02171442 Boehringer Ingelheim Lafiyayyan Afrilu 2002

Mataki na 1

Saukewa: NCT02170896 Boehringer Ingelheim Lafiyayyan Oktoba 2001

Mataki na 1

Saukewa: NCT02173730 Boehringer Ingelheim Lafiyayyan Nuwamba 2002

Mataki na 1

Saukewa: NCT02170623 Boehringer Ingelheim Lafiyayyan Fabrairu 2002

Mataki na 1

Saukewa: NCT02170116 Boehringer Ingelheim Lafiyayyan Nuwamba 1998

Mataki na 1

Saukewa: NCT02170597 Boehringer Ingelheim Lafiyayyan Agusta 2003

Mataki na 1

Saukewa: NCT01225822 Boehringer Ingelheim Venous Thromboembolism Nuwamba 2002

Mataki na 2

Saukewa: NCT02170701 Boehringer Ingelheim Venous Thromboembolism Oktoba 2000

Mataki na 2

Saukewa: NCT02170740 Boehringer Ingelheim Lafiyayyan Nuwamba 1999

Mataki na 1

Saukewa: NCT02170922 Boehringer Ingelheim Lafiyayyan Yuli 1999

Mataki na 1

Tsarin sinadaran

Dabigatran Etexalate Mesylate

CERTIFICATION

2018 GMP-2
原料药GMP证书201811 (captopril, thalidomide da dai sauransu)
GMP-na-PMDA-in-Chanyoo-平成28年08月03日 Nantong-Chanyoo-Pharmatech-Co
FDA-EIR-Letter-201901

INGANTACCEN KYAUTA

Gudanar da inganci1

Shawara18Ayyukan Ƙididdigar Ingancin Ingancin waɗanda suka amince4, kuma6ayyukan suna ƙarƙashin amincewa.

Gudanar da inganci2

Babban tsarin kula da ingancin ingancin ƙasa da ƙasa ya kafa tushe mai ƙarfi don siyarwa.

Gudanar da inganci3

Ingantattun kulawa yana gudana cikin duk tsawon rayuwar samfurin don tabbatar da inganci da tasirin warkewa.

Gudanar da inganci4

Mawakan da ake gudanarwa na kwararru yana tallafawa ingancin bukatun yayin aikace-aikacen da rajista.

SAMUN SARAUTA

cpf5
cpf6

Layin Packaging Bottled na Koriya Countec

cpf7
cpf8

Layin Marufi na CVC Taiwan

cpf9
cpf10

Layin Packaging Board CAM na Italiya

cpf11

Jamus Fette Compacting Machine

cpf12

Japan Viswill Tablet Detector

cf14-1

Dakin Kulawa na DCS

ABUNCI

Hadin gwiwar kasa da kasa
Hadin gwiwar kasa da kasa
Hadin kai na cikin gida
Hadin kai na cikin gida

  • Na baya:
  • Na gaba:

  • Ku rubuta sakonku anan ku aiko mana